<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="117644">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01878669</url>
  </required_header>
  <id_info>
    <org_study_id>ozaydin289</org_study_id>
    <nct_id>NCT01878669</nct_id>
  </id_info>
  <brief_title>Effects of N-acetyl Cysteine During Percutaneous Coronary Intervention</brief_title>
  <acronym>EASE-PCI</acronym>
  <official_title>Effects of N-acetyl Cysteine on Periprocedural Myocardial Infarction and Major Cardiac and Cerebral Events in Patients Undergoing Percutaneous Coronary Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Suleyman Demirel University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Suleyman Demirel University</source>
  <oversight_info>
    <authority>Turkey: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the effects of N-acetyl cysteine on periprocedural
      myocardial infarction and major cardiac and cerebral events in patients undergoing
      percutaneous coronary intervention and who have moderate to high risk for contrast induced
      nephropathy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>periprocedural myocardial infarction</measure>
    <time_frame>postprocedural 3-6 h</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>NAC side effects (Asthma exacerbation, pruritus, dyspnea)</measure>
    <time_frame>during hospitalization at 48 hours</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>major cardiac and cerebral events</measure>
    <time_frame>1 year follow-up</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>30 mg/kg/15 min intravenous bolus preprocedural and 50 mg/kg/8 h intravenous infusion during and after the procedure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>n-acetyl cysteine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 mg/kg/15 min intravenous bolus preprocedural and 50 mg/kg/8 h intravenous infusion during and after the procedure</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-acetyl cysteine</intervention_name>
    <arm_group_label>n-acetyl cysteine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <arm_group_label>saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients &gt; 18 years old undergoing percutaneous coronary intervention and who have
             moderate to high risk for contrast induced nephropathy (Mehran Score â‰¥ 5)

        Exclusion Criteria:

          -  Primary percutaneous coronary intervention

          -  Low risk for contrast induced nephropathy (Mehran Score &lt; 5)

          -  Use of nephrotoxic agents (NSAIDs, aminoglycosides,recent contrast injection...)

          -  Infection

          -  Pregnancy, Lactation

          -  Renal failure requiring dialysis

          -  Hepatic failure

          -  History allergy for NAC

          -  History of Asthma

          -  Chronic nitrate usage

          -  Malignancy

          -  Use of corticosteroids

          -  Leukocytosis,Thrombocytosis,Anemia

          -  Blood pressure of &gt;180/100mmHg despite anti-hypertensive therapy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Suleyman Demirel University</name>
      <address>
        <city>Isparta</city>
        <state>Mediterranean Region</state>
        <zip>32260</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dogan Erdogan, deputy chief physician</last_name>
      <phone>+0902462324479</phone>
      <phone_ext>1140</phone_ext>
      <email>aydoganer@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>mehmet ozaydin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>ibrahim ersoy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 13, 2014</lastchanged_date>
  <firstreceived_date>March 26, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Suleyman Demirel University</investigator_affiliation>
    <investigator_full_name>Mehmet Ozaydin, MD</investigator_full_name>
    <investigator_title>MD, Professor</investigator_title>
  </responsible_party>
  <keyword>n-acetyl cysteine</keyword>
  <keyword>percutaneous coronary intervention</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
